Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by Catalent Biologics at PEGS
SOMERSET, N.J. – August 25, 2020 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
On Wednesday, Sept. 2 at 9:45 a.m. EDT, Gregory Bleck, Ph.D., Global Head of R&D, Catalent Biologics, will present “GPEx® Boost – A Novel Approach for High-Expressing CHO Cell Line Engineering” during the “Optimizing Protein Expression” stream. Dr. Bleck will explain how the next generation of Catalent’s GPEx cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.
Also on Wednesday, at 3:05 p.m. EDT, during the “Engineering Antibody-Drug Conjugates” stream, Robyn Barfield, Ph.D., Group Leader, Catalent Biologics, will discuss Catalent’s proprietary SMARTag® technology, which uses a simple, robust manufacturing process to generate stable, site-specific antibody-drug conjugates (ADCs). In her presentation, titled “Novel SMARTag Linkers Enable Better-Tolerated ADCs,” Dr. Barfield will discuss how the technology can offer wider therapeutic windows, illustrated through a comparison between Catalent’s anti-HER2 RED-106 ADC, and the related drug, T-DM1.
During the virtual event, Dr. Barfield will also present the case study in her presentation as a poster, “A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels.”
Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor’s degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign, working in the areas of gene regulation and expression. At Catalent, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.
Dr. Barfield has more than 10 years’ experience working in bioconjugation, and joined Catalent Biologics when it acquired Redwood Bioscience in 2014. She has a doctorate in cell and molecular biology from the University of Pennsylvania School of Medicine and a bachelor’s degree in genetics and cell biology, from the University of Georgia.
Catalent, GPEx and SMARTag are registered trademarks of Catalent, Inc. or its affiliates or subsidiaries.
About Catalent Biologics
Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com